Andrea R. Lindell, serving as a director for Chemed Corp (NYSE: CHE), completed a transaction disposing of 1,347 shares of the company's capital stock on June 9, 2026. The aggregate value of this disposition reached $602,553. The shares were liquidated at a unit price of $447.33, a figure that sits marginally above the contemporaneous stock price of $439.55. Following the execution of this sale, Ms. Lindell's direct ownership position in Chemed Corp stands at 4,578 shares.
The insider transaction occurs against a backdrop of recent operational and financial developments for Chemed. The company reported first-quarter earnings for 2026 that surpassed analyst consensus. Earnings per share came in at $5.65, exceeding the projected figure of $5.34. Top-line revenue also outperformed estimates, reaching $657.5 million compared to the anticipated $651.02 million. In response to these results, RBC Capital adjusted its price target for Chemed upward to $436 from $422, while maintaining a Sector Perform rating.
Corporate governance activities also took place during this period. Chemed held its annual meeting of stockholders, where all eight board nominees were elected and the independent auditor was ratified. However, the meeting concluded with shareholders rejecting the proposed executive compensation plan. This rejection highlights a divergence between shareholder sentiment on governance matters and the company's operational performance.
Financial health metrics from InvestingPro analysis indicate that Chemed appears undervalued at current levels, supported by a "GOOD" financial health rating. The company has also demonstrated a consistent commitment to shareholder returns, having raised its dividend for 17 consecutive years. These factors are highlighted in InvestingPro Tips as indicators of strong shareholder commitment despite the recent insider sale.